|Jmol-3D images||Image 1|
|Molar mass||284.36 g mol−1|
| (what is: / ?)
Except where noted otherwise, data are given for materials in their standard state (at 25 °C (77 °F), 100 kPa)
Taurolidine ([bis(1,1-dioxoperhydro-1,2,4-thiadiazinyl-4)-methane) is a drug with antimicrobial and anti-lipopolysaccharide properties. Derived from the amino acid taurine, its immunue modulatory action is reported to be mediated with priming and activation of macrophages and polymorphonuclear leukocytes.
Taurolidine has been used to treat patients with peritonitis and as an antiendoxic agent in patients with systemic inflammatory response syndrome. Additionally, taurolidine demonstrates some anti-tumor properties, with positive results seen in early-stage clinical investigations using the drug to treat gastrointestinal malignancies and tumors of the central nervous system.
Taurolidine has been investigated for the prevention of central venous catheter-related infections, and there is ample evidence that the addition of taurolidine significantly decreases infection rates.     
- Watson RW, Redmond HP, Mc Carthy J, Bouchier-Hayes D (September 1995). "Taurolidine, an antilipopolysaccharide agent, has immunoregulatory properties that are mediated by the amino acid taurine". J. Leukoc. Biol. 58 (3): 299–306. PMID 7665985.
- Jacobi CA, Menenakos C, Braumann C (October 2005). "Taurolidine--a new drug with anti-tumor and anti-angiogenic effects". Anticancer Drugs 16 (9): 917–21. doi:10.1097/01.cad.0000176502.40810.b0. PMID 16162968.
- Solomon, LR et al (June 2010). "A Randomized Double-Blind Controlled Trial of Taurolidine-Citrate Catheter Locks for the Prevention of Bacteremia in Patients Treated with Hemodialysis". American Journal of Kidney Disease 55 (6): 1060–1068. PMID 20207458.
- Koldehoff M. and Zakrzewski J.L. (June 2004). "Taurolidine is effective in the treatment of central venous catheter-related bloodstream infections in cancer patients". International Journal of Antimicrobial Agents 24: 491–495. PMID 15519483.
- Simon A., Ammann R.A., Wiszniewsky G., Bode U., Fleischhack G., and Besuden M.M. (June 2008). "Taurolidine-citrate lock solution significantly reduces CVAD-associated grampositive infections in pediatric cancer patients". BMC Infectious Diseases 8. PMID 18664278.
- Betjes M.G.H. and van Agteren M. (February 2004). "Prevention of dialysis catheter-related sepsis with a citrate-taurolidine-containing lock solution". Nephrol Dial Transplant 19: 1546–1551. PMID 14993498.
- Handrup M.M., Moller, J.K., and Schroder, H. (February 2013). "Central Venous Catheters and Catheter Locks in Children With Cancer: A Prospective Randomized Trial of Taurolidine Versus Heparin". Pediatr Blood Cancer 60: 1292–1298. PMID 23417891.
|This drug article relating to the blood and blood forming organs is a stub. You can help Wikipedia by expanding it.|